Submission of Immunovia CPT PLA code for IMMray™ PanCan-d test is on the agenda of the American Medical Association
LUND, Sweden, April 14, 2022 /PRNewswire/ — Immunovia, Inc., the U.S. subsidiary of Immunovia AB (Nasdaq Stockholm: IMMNOV), has submitted a Current Procedural Terminology (CPT) Proprietary Laboratory Analysis (PLA) code request to the American Medical Association (AMA) for the IMMray PanCan-d test.
A PLA code for IMMray PanCan-d would allow healthcare professionals to specifically identify IMMray PanCan-d when submitting information and claims to health insurers and payers.
The PLA submission by Immunovia will be reviewed and voted on by the Technical Advisors Group on May 13and during a round table. If approved, the issued PLA code will be published on July 1, 2022and would be effective on October 1, 2022.
CPT codes provide physicians and healthcare professionals with a uniform language for coding medical services and procedures. It is the most widely accepted medical nomenclature used in the United States to report physician and health care professional services, including laboratory tests under public and private health insurance programs.
PLA codes are an addition to the CPT code set approved by the AMA CPT Editorial Board. These are alphanumeric CPT codes with a corresponding descriptor for labs or manufacturers who wish to more accurately identify their test.
For more information please contact:
CEO and Acting President
E-mail: [email protected]
Senior Director of Investor Relations and Corporate Communications
E-mail: [email protected]
Tel: +46 736 36 35 74
This is information that Immunovia is required to make public under the EU Market Abuse Regulation. The information has been submitted for publication, through the contact person listed above, to 08:45 CET April 142022.
Immunovia AB is a diagnostics company with a vision to revolutionize blood diagnostics and increase survival rates for cancer patients.
Our first product, IMMray™ PanCan-d is the only blood test currently available specifically for the early detection of pancreatic cancer. The test has unparalleled clinical performance. Commercialization of IMMray™ PanCan-d began in August 2021 in the UNITED STATES and IMMray™ PanCan-d is offered as a laboratory-developed test (LDT) exclusively by Immunovia, Inc. For more information, visit: www.immunovianc.com.
Immunovia is collaborating and engaging with healthcare providers, leading experts and patient advocacy groups around the world to make this test available to all high-risk pancreatic cancer groups.
the UNITED STATESthe first market in which IMMray™ PanCan-d is commercially available, is the world’s largest market for the detection of pancreatic cancer with an estimated value of more than $4 billion annually.
Immunovia (IMMNOV) shares are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
SOURCE Immunovia AB